By Fineline Cube 
China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its generic version of Sedapain (eptazocine), a drug developed by Japan’s Nichi-Iko Pharmaceutical Co., Ltd. This approval marks the first generic eptazocine to be approved in China.
Drug Profile
Eptazocine, classified as a psychotropic drug (Class II) in China, is indicated for pain relief, particularly for cancer-related pain and postoperative pain management. Yifan Pharma’s generic version is registered as a Category III chemical drug and has successfully passed the generic quality consistency evaluation.
Market Background
Yifan Pharma’s achievement highlights its commitment to expanding its portfolio of high-quality generic medications. The approval underscores the company’s capabilities in meeting stringent regulatory standards and contributing to the accessibility of essential pain management therapies in China.
Future Outlook
With this approval, Yifan Pharma is well-positioned to address the growing demand for cost-effective pain relief solutions. The company is expected to leverage its market presence and distribution networks to ensure the broad availability of this newly approved generic medication.-Fineline Info & Tech